Thursday, February 25, 2021

Viracta Therapeutics Goes Public Via Reverse Merger, Gets $65M

San Diego-based Viracta Therapeutics has gone public via a reverse merger with Sunesis Pharmaceuticals, and raised $65M in a private placement, the company said late Wednesday. According to the company, as a result of the merger, it will start trading on the Nasdaq Global Select Market this morning under the ticker symbol VIRX. Viracta's lead prog

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.